CASI Pharmaceuticals, Inc. (NASDAQ:CASI)’s share price shot up 9.7% during trading on Friday . The stock traded as high as $3.18 and last traded at $3.06. 526,731 shares were traded during trading, an increase of 90% from the average session volume of 277,383 shares. The stock had previously closed at $2.79.

Several research firms recently commented on CASI. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Finally, ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 15th.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. equities analysts anticipate that CASI Pharmaceuticals, Inc. will post -0.15 earnings per share for the current year.

In other news, Director Wei-Wu He purchased 173,500 shares of the company’s stock in a transaction on Monday, September 18th. The stock was acquired at an average price of $1.75 per share, with a total value of $303,625.00. Following the transaction, the director now directly owns 513,525 shares of the company’s stock, valued at approximately $898,668.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired a total of 681,002 shares of company stock valued at $1,227,754 in the last three months. 24.52% of the stock is currently owned by corporate insiders.

WARNING: “CASI Pharmaceuticals (CASI) Shares Up 9.7%” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Stock Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related stocks with our FREE daily email newsletter.